3.68 USD
+0.14 (+3.95%)
At close: Feb 6, 2026
3.68 USD
0 (0%)
After Hours: 2/6/2026, 8:11:12 PM
We assign a fundamental rating of 2 out of 10 to VYGR. VYGR was compared to 523 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for VYGR as it has an excellent financial health rating, but there are worries on the profitability. VYGR has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- VYGR had negative earnings in the past year.
- VYGR had a negative operating cash flow in the past year.
- The reported net income has been mixed in the past 5 years: VYGR reported negative net income in multiple years.
- In the past 5 years VYGR reported 4 times negative operating cash flow.
1.2 Ratios
- VYGR has a Return On Assets (-43.75%) which is in line with its industry peers.
- VYGR has a Return On Equity of -57.27%. This is in the better half of the industry: VYGR outperforms 63.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -43.75% | ||
| ROE | -57.27% | ||
| ROIC | N/A |
ROA(3y)-2.68%
ROA(5y)-6.15%
ROE(3y)-14.79%
ROE(5y)-19.09%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- VYGR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- VYGR does not have a ROIC to compare to the WACC, probably because it is not profitable.
- VYGR has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for VYGR has been increased compared to 5 years ago.
- VYGR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- Based on the Altman-Z score of -0.96, we must say that VYGR is in the distress zone and has some risk of bankruptcy.
- VYGR has a Altman-Z score (-0.96) which is in line with its industry peers.
- VYGR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.96 |
ROIC/WACCN/A
WACC12.44%
2.3 Liquidity
- A Current Ratio of 6.29 indicates that VYGR has no problem at all paying its short term obligations.
- VYGR has a better Current ratio (6.29) than 64.19% of its industry peers.
- VYGR has a Quick Ratio of 6.29. This indicates that VYGR is financially healthy and has no problem in meeting its short term obligations.
- VYGR has a Quick ratio of 6.29. This is in the better half of the industry: VYGR outperforms 65.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.29 | ||
| Quick Ratio | 6.29 |
3. Growth
3.1 Past
- VYGR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -404.23%.
- Looking at the last year, VYGR shows a very negative growth in Revenue. The Revenue has decreased by -80.88% in the last year.
- Measured over the past years, VYGR shows a decrease in Revenue. The Revenue has been decreasing by -5.18% on average per year.
EPS 1Y (TTM)-404.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-193.75%
Revenue 1Y (TTM)-80.88%
Revenue growth 3Y28.85%
Revenue growth 5Y-5.18%
Sales Q2Q%-45.73%
3.2 Future
- VYGR is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -6.88% yearly.
- Based on estimates for the next years, VYGR will show a decrease in Revenue. The Revenue will decrease by -8.25% on average per year.
EPS Next Y-88.71%
EPS Next 2Y-20.23%
EPS Next 3Y-8.08%
EPS Next 5Y-6.88%
Revenue Next Year-60.65%
Revenue Next 2Y-17.78%
Revenue Next 3Y-6.68%
Revenue Next 5Y-8.25%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- VYGR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year VYGR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- VYGR's earnings are expected to decrease with -8.08% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-20.23%
EPS Next 3Y-8.08%
5. Dividend
5.1 Amount
- VYGR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
3.68
+0.14 (+3.95%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10/bmo
Earnings (Next)03-09 2026-03-09/amc
Inst Owners55.09%
Inst Owner Change-1.46%
Ins Owners0.88%
Ins Owner Change-0.21%
Market Cap204.61M
Revenue(TTM)31.32M
Net Income(TTM)-126.00M
Analysts87.78
Price Target15.3 (315.76%)
Short Float %7.41%
Short Ratio6.39
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.56%
Min EPS beat(2)-6.33%
Max EPS beat(2)11.46%
EPS beat(4)1
Avg EPS beat(4)-17.11%
Min EPS beat(4)-57.86%
Max EPS beat(4)11.46%
EPS beat(8)5
Avg EPS beat(8)79.25%
EPS beat(12)8
Avg EPS beat(12)75.9%
EPS beat(16)10
Avg EPS beat(16)73.9%
Revenue beat(2)1
Avg Revenue beat(2)9.1%
Min Revenue beat(2)-48.55%
Max Revenue beat(2)66.75%
Revenue beat(4)1
Avg Revenue beat(4)-24.46%
Min Revenue beat(4)-62.87%
Max Revenue beat(4)66.75%
Revenue beat(8)5
Avg Revenue beat(8)80.35%
Revenue beat(12)8
Avg Revenue beat(12)85.04%
Revenue beat(16)10
Avg Revenue beat(16)78%
PT rev (1m)0%
PT rev (3m)-4.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.41%
EPS NY rev (1m)0%
EPS NY rev (3m)1.13%
Revenue NQ rev (1m)-0.03%
Revenue NQ rev (3m)-0.47%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)18.13%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 6.53 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.93 | ||
| P/tB | 0.93 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.16
EYN/A
EPS(NY)-1.63
Fwd EYN/A
FCF(TTM)-2.13
FCFYN/A
OCF(TTM)-2.09
OCFYN/A
SpS0.56
BVpS3.96
TBVpS3.96
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -43.75% | ||
| ROE | -57.27% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-2.68%
ROA(5y)-6.15%
ROE(3y)-14.79%
ROE(5y)-19.09%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.11
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 52.74% | ||
| Cap/Sales | 6.77% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.29 | ||
| Quick Ratio | 6.29 | ||
| Altman-Z | -0.96 |
F-Score2
WACC12.44%
ROIC/WACCN/A
Cap/Depr(3y)62.69%
Cap/Depr(5y)107.19%
Cap/Sales(3y)3.93%
Cap/Sales(5y)4.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-404.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-193.75%
EPS Next Y-88.71%
EPS Next 2Y-20.23%
EPS Next 3Y-8.08%
EPS Next 5Y-6.88%
Revenue 1Y (TTM)-80.88%
Revenue growth 3Y28.85%
Revenue growth 5Y-5.18%
Sales Q2Q%-45.73%
Revenue Next Year-60.65%
Revenue Next 2Y-17.78%
Revenue Next 3Y-6.68%
Revenue Next 5Y-8.25%
EBIT growth 1Y-1309.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-78.78%
EBIT Next 3Y-14.55%
EBIT Next 5Y-12.11%
FCF growth 1Y-237.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-229.85%
OCF growth 3YN/A
OCF growth 5YN/A
VOYAGER THERAPEUTICS INC / VYGR FAQ
What is the fundamental rating for VYGR stock?
ChartMill assigns a fundamental rating of 2 / 10 to VYGR.
What is the valuation status of VOYAGER THERAPEUTICS INC (VYGR) stock?
ChartMill assigns a valuation rating of 0 / 10 to VOYAGER THERAPEUTICS INC (VYGR). This can be considered as Overvalued.
What is the profitability of VYGR stock?
VOYAGER THERAPEUTICS INC (VYGR) has a profitability rating of 1 / 10.
Can you provide the financial health for VYGR stock?
The financial health rating of VOYAGER THERAPEUTICS INC (VYGR) is 7 / 10.
Can you provide the expected EPS growth for VYGR stock?
The Earnings per Share (EPS) of VOYAGER THERAPEUTICS INC (VYGR) is expected to decline by -88.71% in the next year.